SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 14 of 21
Word Count: 1334
Character Count: 8464

Document Content:

amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities; (c) the issuance by the Company of stock options or other stock-based awards or the issuance by the Company of shares of capital stock of the Company under any equity compensation or incentive plan of the Company described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (d) any warrants issued by the Company pursuant to Section 7.4 hereunder as a Future Financing Fee (or any securities underlying any such warrants); provided that in the case of (b) and (c) above, each recipient of such shares of Common Stock shall be contractually prohibited from selling, offering, disposing of or otherwise transferring any such shares during the remainder of the Lock-Up Period.

Release of D&O Lock-Up Period. If the Representative, in its sole discretion, agrees to release or waive the restrictions
set forth in the Lock-Up Agreements described in Section 2.24 hereof for an officer or director of the Company and provides the Company
with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver, the
Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit B hereto through
a major news service at least two (2) Business Days before the effective date of the release or waiver.

Blue Sky Qualifications. The Company shall use its commercially reasonable efforts, in cooperation with the Underwriters, if necessary,
to qualify the Public Shares, the Representative’s Warrants and the Representative Warrant Shares for offering and sale under the
applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative may designate and to maintain
such qualifications in effect so long as required to complete the distribution of the applicable securities; provided, however, that
the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer
in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any
jurisdiction in which it is not otherwise so subject.

Reporting Requirements. The Company, during the period when a prospectus relating to the Public Shares, the Representative’s
Warrants and/or the Representative Warrant Shares is (or, but for the exception afforded by Rule 172, would be) required to be delivered
under the Securities Act, will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time
periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company shall report the use of proceeds from the
issuance of the Public Shares, the Representative’s Warrants and the Representative Warrant Shares as may be required under Rule
463 under the Securities Act Regulations.

Representative Warrant Shares Reserved. The Company shall, at all times while any Representative’s Warrants are outstanding,
reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely
for the purpose of enabling it to issue Representative Warrant Shares upon exercise of the Representative’s Warrants, the number
of Representative Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding Representative’s
Warrants.

Conditions of Underwriters’ Obligations. The obligations of the Underwriters to purchase and pay for the Public Shares,
as provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date
hereof and as of the Closing Date and any Option Closing Date; (ii) the accuracy of the statements of officers of the Company made pursuant
to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:

Regulatory Matters.

Effectiveness of Registration Statement; Rule 430A Information. The Registration Statement has become effective not later than
5:30 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at
the Closing Date and at any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or
the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s
knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information.
The Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame
required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been
filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.

FINRA Clearance. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the
amount of compensation allowable or payable to the Underwriters as described in the Registration Statement.

Exchange Stock Market Clearance. On the Closing Date and on any Option Closing Date, the Firm Shares or the Option Shares, as
the case may be, shall have been duly approved for listing on the Exchange, subject only to official notice of issuance.

Company Counsel Matters.

Opinion of Counsel. On the Closing Date and on any Option Closing Date, the Representative shall have received the favorable opinions
of (i) Company Counsel and (ii) Nixon & Vanderhye PC, special intellectual property counsel to the Company, each dated the Closing
Date or the applicable Option Closing Date and addressed to the Representative, in form and substance reasonably satisfactory to the
Representative.

Reliance. In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the
laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified
in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other
counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent
they deem proper, on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions
having custody of documents respecting the corporate existence or good standing of the Company, provided that copies of any such statements
or certificates shall be delivered to Representative Counsel if requested.

Comfort Letters.

Comfort Letter. At the time this Agreement is executed you shall have received a comfort letter from the Auditor containing statements
and information of the type customarily included in accountants’ comfort letters with respect to the financial statements and certain
financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representative
and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement and with a specified
date therein not more than two (2) Business Days prior to the date of this Agreement.

Bring-down Comfort Letter. At the Closing Date and at any Option Closing Date, the Representative shall have received from the
Auditor a letter, dated as of the Closing Date or the applicable Option Closing Date, to the effect that the Auditor reaffirms the statements
made in the letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date no earlier than the
later of (i) the date of this Agreement and (ii) the date that is two (2) Business Days prior to the Closing Date or the applicable Option
Closing Date.

Officers’ Certificates.